NCT05139030View on ClinicalTrials.gov

Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty

PHASE3CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions
Knee OsteoarthritisPain Management
Interventions
DRUG

bupivacaine liposome injectable suspension

Adductor canal block with EXPAREL

DRUG

Bupivacaine Hydrochloride

Adductor Canal Block with bupivacaine HCl

Trial Locations (6)

45417

Midwest Clinical Research Center, LLC, Dayton

72211

Woodland International Research Group, Little Rock

75006

HD Research- Legent Orthopedic Hospital, Carrollton

77401

First Surgical Hospital, Bellaire

78240

Endeavor Clinical Trials, San Antonio

91105

Lotus Clinical Research, Pasadena

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT05139030 - Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter